Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia
Andrew M. Brunner(Harvard University), Amir Fathi(Massachusetts General Hospital), Seth A. Wander(Harvard University), Meghan Burke(Harvard University), Yi‐Bin Chen(Massachusetts General Hospital), Hossein Sadrzadeh(Boston University), Karen K. Ballen(University of Virginia Health System), Ilene Galinsky(Dana-Farber Cancer Institute), A. John Iafrate(Massachusetts General Hospital), Sophia Adamia(Beth Israel Deaconess Medical Center), Gabriela Hobbs(Massachusetts General Hospital), Richard M. Stone(Dana-Farber Cancer Institute), Ashley Perry(Harvard University), Aura Y. Ramos(Harvard University), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Regina Silver(Harvard University), Donna Neuberg(Otsuka (Japan)), Christelle Joseph(Harvard University), Philip C. Amrein(Massachusetts General Hospital)
Cited by 6
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k